ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ
|
|
- Brooke Black
- 6 years ago
- Views:
Transcription
1 ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ Β ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΠΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ 9 Ο Βορειοελλα
2 ATRIAL FIBRILATION Atrial fibrillation (AF) is the most common clinically significant heart rhythm disorder, with an estimated lifetime risk of 22% to 26% or a lifetime risk of 1 in 4 In the European Union, there were 8.8 million adults >55 years of age with AF in 2010.Expected increase to 17.9 million by 2060 These statistics do not account for silent or undiagnosed AF, which is thought to affect as many as one third of the U.S. population
3 ATRIAL FIBRILATION AF associated morbidity: troublesome symptoms, heart failure, and thromboembolic events Drug and nonpharmacologic therapies that control rhythm or rate usually improve symptoms and heart failure The results of the therapy applied are usually judged on the basis of both the absence of clinical symptoms and documentation of sinus rhythm on every available electrocardiographic (ECG) recording Routine office ECGs, occasional 24-hour ambulatory ECG and, more seldom, longer term ECG event recording are the monitoring strategies usually adopted.
4 BENEFIT/RISK The concern is that asymptomatic and/or undetected recurrences of AF could expose patients to equally increased risks of stroke and thromboembolic events
5 ASYMPTOMATIC AF In about 25% of patients with ischemic strokes, no etiologic factor is identified Many patients with AF have no symptoms from the arrhythmia Many patients with episodes of AF (even permanent AF) may be unaware of the arrhythmia Patients with symptomatic episodes of AF also have many episodes asymptomatic asymptomatic intermittent AF is still poorly understood: inherently difficult to characterize and quantitate. Temporal relation between stroke/af! Prognostic significance of short episodes of asymptomatic AF, (as typically detected by pacemakers), is unknown
6 TEMPORAL DISSOCIATION BETWEEN SYMPTOMS AND AF Symptoms attributed to AF have a relatively low positive predictive value for AF Among patients with symptomatic bradycardia and a history of atrial fibrillation, symptoms of atrial fibrillation often were not associated with documented atrial tachyarrhythmias, and more than 90% of atrial tachyarrhythmias were clinically silent Strickberger et al Symptoms and Atrial Fibrillation Heart Rhythm, Vol 2, No 2, February 2005
7 ASYMPTOMATIC AF: INCIDENCE 38% asymptomatic reccurences JACC Vol. 43, No. 1, 2004 Israel et al. 49 Asymptomatic AF January 7, 2004:47 52
8 Cryptogenic Stroke and Underlying Atrial Fibrillation CRYSTAL
9 Low sensitivity and NP Value of classical monitoring tools Botto et al. AF and the Risk of Thromboembolic Events
10 DEVICE DETECTED ASYMPTOMATIC AF
11 Prognostic implications of asymptomatic AF
12 Circulation April 1, 2003 Glotzer et al AHREs Predict Death and Stroke
13 Atrial High Rate Episodes Predict Death and Stroke Presence of any AHRE(trial rate was 220 bpm for 5 minutes),meant that a patient was 2.5 times more likely to die 2.8 times more likely to die or have a nonfatal stroke nearly 6 times as likely to develop AF as one without any AHRE 6 year f up
14 ASYMPTOMATIC AF: PROGNOSTIC SIGNIFICANCE Capucci et al. JACC Vol. 46, No. 10, 2005 Arterial Embolism in Bradycardia Patients Italian AT500 Registry
15 2580 patients, 65 years, with hypertension and no history of atrial fibrillation, with a recently been implanted pacemaker or ICD. Subclinical atrial tachyarrhythmias :episodes of atrial rate >190 beats per minute for more than 6 minutes Follow up for a mean of 2.5 years for the primary outcome of ischemic stroke or systemic embolism
16 ASSERT Device detected Atrial Fibrilation 2,5 fold risk SCAF was detected by a pacemaker or an ICD in nearly 40% of patients during 2½ years of follow up lack of temporal association between SCAF and stroke or systemic embolism ASSERT does not provide any evidence that oral anticoagulation will have the same effectiveness in this population as it does for patients with clinical AF
17 Relationship between AF burden, as detected by an implanted CIED, and stroke/thromboembolism
18 RISC /BENEFIT (OACS) patients with CHADS2 score = 0 are at low risk, even if they have longlasting AF episodes patients with CHADS2 score 3 should be considered at high risk even when AF is no longer detected Botto et al. AF and the Risk of Thromboembolic Events
19 The net benefit of antithrombotic treatment is well established in patients with clinical atrial fibrillation, but there may not be a similar benefit in patients with subclinical atrial tachyarrhythmias
20 ARTESIA Apixaban for the Reduction of Thrombo-Embolism in patients with device detected Subclinical Atrial Fibrilation Primary outcome: Systemic stroke/systemic embolism and major bleeding Inclusion criteria: AF detection by Pacemaker/ICD/ILR 1 episode of subclinical AF 6min but no episode>24h,chads₂vasc score 4 Exclusion criteria: AF documented by surface ECG 6min,creatinine 2,5,creatinine clearence<25ml/min Randomisation:81mg ASA vs APIXABAN 2,5/5mg bid Mean follow up :3years
21 Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH) investigator-initiated, prospective, parallel-group, double-blind, randomised, multi-centre trial. Edoxaban vs ASA to pre-vent stroke, systemic embolism, or cardiovascular death in patients with AHRE 180 bpm atrial rate and 6 min duration and at least two stroke risk factors but without AF
22 ASYMPTOMATIC AF CONCLUSIONS combining data on AF absence, presence, and duration with CHADS2 score can discriminate between low- and high-risk patients within the same population the standard methods of AF monitoring have a low sensitivity and a low negative predictive value. This may impact on the management of antiarrhythmic and antithrombotic therapy, especially in patients with a moderate risk of embolic events absence of AF could guarantee low-moderate thromboembolic risk in patients with CHADS2 score 1, and 2, while it does not in patients with CHADS2 score 3
23 ASYMPTOMATIC AF CONCLUSIONS Current Guidelines still the only valid Device memory should not be ignored for AF management(though not mentioned in current Guidelines) Confirm it s really AF! Suggested treatment (on debate! Intervention trials still ongoing) : CHADS₂=0 : NO OAC CHADS₂=1-2: OAC if AF 24h duration and low bleeding risk CHADS₂ 3 : OAC if AF 6 min duration The threshold of the burden of asymptomatic, subclinical AF associated with a beneficial effect of oral anticoagulants remains unknown.
24 ΕΥΧΑΡΙΣΤΩ
25 ATRIAL FIBRILATION when AF is deemed to have been completely suppressed or cured, physicians may stop anticoagulation in an effort to avoid the unnecessary risks, burden, and inconvenience of OAC therapy The concern is that asymptomatic and/or undetected recurrences of AF could expose patients to increased risks of ischemic stroke and thromboembolic events
26 Documentation of atrial fibrillation is required to initiate anticoagulant therapy after ischemic stroke often paroxysmal and asymptomatic nature of atrial fibrillation, it may not be detected with the use of traditional monitoring techniques. Current guidelines suggest performing 24 or more hours of ECG monitoring to rule out atrial fibrillation in patients with an ischemic stroke but acknowledge that the most effective duration of monitoring has not been determined Most of the episodes of atrial fibrillation that were detected in our study were asymptomatic (74% at 6 months and 79% at 12 months in the ICM group). This finding, in combination with the paroxysmal nature of atrial fibrillation after cryptogenic stroke, may account for the low yield of diagnostic strategies based on symptom occurrence or the use of intermittent short-term recordings,(crystal)
27
28 Botto et al. AF and the Risk of Thromboembolic Events
29 Embolic Stroke of unknown Source (ESUS) Approximately 25% of ischemic strokes appear cardioembolic (typical CT/MRI-clinical presentation) but no source can be detected by TOE-Holter. Paroxysmal asymptomatic undetected AF? Best detection achieved by Implantable Loop Recorder(ILR).
Defining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationCausal relationship between AF & stroke
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationCausal relationship between AF & stroke
7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,
More informationDiagnosing atrial fibrillation using implantable devices
Diagnosing atrial fibrillation using implantable devices Axel Brandes, MD, FESC Associate Professor of Electrophysiology and Cardiac Arrhythmias Dept. of Cardiology, Odense University Hospital, DK HRC
More informationFibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici?
Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici? Fabrizio Ammirati Dipartimento Medicina UOC Cardiologia Ospedale GB Grassi ASL Roma 3 Sept 2013 Patients
More informationDevice Diagnostics and Stroke Prevention: State of the Art
Device Diagnostics and Stroke Prevention: State of the Art Ass. Prof. Dr. Carsten W. Israel Dept. of Cardiology Evangelical Hospital Bielefeld Germany C.W.Israel@em.uni-frankfurt.de Disclosure of Relationships
More informationSUBCLINICAL ATRIAL FIBRILLATION IN PATIENTS WITH IMPLANTABLE DEVICEs ORAL ANTICOAGULANT THERAPY: TO GIVE OR NOT TO GIVE, THIS IS THE PROBLEM!!
SUBCLINICAL ATRIAL FIBRILLATION IN PATIENTS WITH IMPLANTABLE DEVICEs ORAL ANTICOAGULANT THERAPY: TO GIVE OR NOT TO GIVE, THIS IS THE PROBLEM!! Atrial tachycardia «ATRIAL HIGH RATES EPISODES» (AHREs) Episodes
More informationImplantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use?
Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use? Helmut Pürerfellner, MD, Assoc. Prof. Saint Elisabeth s Sisters Hospital Academic Teaching Center Linz/Austria
More informationECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES
ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January
More informationDevice detected AF and atrial high rate episodes
Device detected AF and atrial high rate episodes Professor Paulus Kirchhof University of Birmingham Institute of Cardiovascular Sciences SWBH and UHB NHS trusts, Birmingham, UK Department of Cardiovascular
More informationAtrial fibrillation (AF) has been the. Subclinical Atrial Fibrillation, Embolic Risk, and Anticoagulant Treatment
MAEDICA a Journal of Clinical Medicine 2018; 13(4): 261-265 https://doi.org/10.26574/maedica.2018.13.4.261 Mædica - a Journal of Clinical Medicine Invited Editorial Point of View Subclinical Atrial Fibrillation,
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationΘα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος;
Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος; Νικόλαος Φραγκάκης Λέκηορας Καρδιολογίας, FESC Ιπποκράηειο
More informationThromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation
48 th Annual New York Cardiovascular Symposium Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation Is Left Atrial Appendage Dysfunction Sufficient to Generate Clots? December
More informationFibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia
Gianluca Botto, FESC Elettrofisiologia Ospedale Sant Anna, Como Fibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia 20 min Presenter Disclosure Information n n n Research
More informationAtrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY Turin October 13-15, 2016 Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients Dott.
More informationΣτυλιανός Τζέης MD, PhD, FESC
Βραχειάς δια ρκειας ριπε ςυπερκοιλιακη ς ταχυαρρυθμιάς στο Holter ρυθμου η στις συσκευε ςδιαχει ρισης του καρδιακου ρυθμου. Θα χορηγη σουμε αντιθρομβωτικη αγωγη ; Στυλιανός Τζέης MD, PhD, FESC Επιμελητής
More informationAsymptomatic Atrial Fibrillation: Detection and Management. 18 December nd Annual Advances in Heart Disease Palace Hotel, San Francisco
Asymptomatic Atrial Fibrillation: Detection and Management 18 December 2015 32 nd Annual Advances in Heart Disease Palace Hotel, San Francisco Zian H. Tseng, M.D., M.A.S. Associate Professor of Medicine
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationThe Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study
The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study Taya V. Glotzer, MD; Emile G. Daoud, MD; D. George Wyse, MD, PhD; Daniel
More informationConsensus document: Screening and Prevention of Atrial Fibrillation
Consensus document: Screening and Prevention of Atrial Fibrillation Yong-Seog Oh, M.D.,Ph.D. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary s Hospital, College of Medicine, The
More informationAF detection: What s new? Christopher B. Granger
AF detection: What s new? Christopher B. Granger Disclosures Research contracts: Apple, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Novartis, GSK, Medtronic Foundation, Pfizer,
More informationPrimary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
More informationTOP 3: EMBRACE. Lucy Vieira MD FRCP Neurologist MUHC. N Engl J Med Volume 370(26): June 26, David J.
TOP 3: EMBRACE N Engl J Med Volume 370(26):2467-2477 June 26, 2014 David J. Gladstone et al Lucy Vieira MD FRCP Neurologist MUHC Receiving research funds AstraZeneca 2014-2016 Original Article Atrial Fibrillation
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationManagement of Atrial Fibrillation. Leon Ptaszek, MD, PhD, FACC, FHRS 25 March 2018
Management of Atrial Fibrillation Leon Ptaszek, MD, PhD, FACC, FHRS 25 March 2018 Disclosures Speaker: St. Jude Medical, Biotronik Consultant: St. Jude Medical, World Care Clinical Objectives Recognize
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationAtrial fibrillation and stroke. Isabelle C Van Gelder University Medical Center Groningen The Netherlands
Atrial fibrillation and stroke Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January 2018 Content Stroke what is the problem for patients with AF?
More informationCryptogenic Stroke: The role of silent Atrial Fibrillation
Cryptogenic Stroke: The role of silent Atrial Fibrillation PD Dr. med. Martin A. Ritter Westfälische Wilhelms-Universität Münster Germany ritterm@uni-muenster.de 1 Turin, 25.10.2014 Agenda 1. What is a
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationNEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION
NEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION MAY 1, 2015 Melissa R. Robinson, MD FACC FHRS CCDS Assistant Professor of Medicine Director of the Complex Arrhythmia Service POINTS TO MAKE
More informationAF Detection During Drug Development: What Constitutes a Signal
AF Detection During Drug Development: What Constitutes a Signal Peter R. Kowey, FACC, FAHA, FHRS Lankenau Heart Institute Jefferson Medical College Philadelphia, PA Disclosure Dr. Kowey has consulted for
More informationSpontaneous Atrial Fibrillation and Noacs and Reversal agents
Spontaneous Atrial Fibrillation and Noacs and Reversal agents Laurent Lewkowiez, MD Regional Service Chief, Hospital Cardiology CPMG Cardiac Electrophysiology Educational Goals relationship between atrial
More informationrequesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group
October 2015 Our Ref: FOI.15.ASH0149 requesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group Original Request Survey attached. Question 1: Between 1 July 2014 and
More informationFibrillazione atriale: è sempre necessario ricercarla, e come?
Fibrillazione atriale: è sempre necessario ricercarla, e come? Domenico Prisco DMSC Università di Firenze SOD Medicina Interna Interdisciplinare AOU Careggi Firenze 23-10-2018 Disclosure Fees for lectures
More informationΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ. ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C
ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C Definitions of AF: A Simplified Scheme Term Definition Paroxysmal AF AF that terminates
More informationECTOPIC BEATS: HOW MANY COUNT?
ECTOPIC BEATS: HOW MANY COUNT? Rupert FG Simpson, 1 Jessica Langtree, 2 *Andrew RJ Mitchell 2 1. King s College Hospital, London, UK 2. Jersey General Hospital, Jersey, UK *Correspondence to mail@jerseycardiologist.com
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationAtrial fibrillation workshop: rate- versus rhythm-control
Atrial fibrillation workshop: rate- versus rhythm-control Rocky Mountain Internal Medicine Conference Nov, 2011 Dr F. Russell Quinn Cardiac Electrophysiologist, Foothills Medical Centre, Calgary Disclosures
More informationAtrial Fibrillation T. Jared Bunch, MD, FACC
Atrial Fibrillation T. Jared Bunch, MD, FACC Director of Heart Rhythm Services, Intermountain Heart Rhythm Specialists, Intermountain Medical Center, Intermountain Healthcare; Salt Lake City, UT Objectives:
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationCan Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015
Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015 Atul Verma, MD FRCPC FHRS Director, Heart Rhythm Program Southlake Regional Health Centre Newmarket, Ontario, Canada Chair,
More informationContinuous ECG telemonitoring with implantable devices: the expected clinical benefits
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Declaration of
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationEHRA CONSENSUS DOCUMENT
Europace (2017) 0, 1 23 doi:10.1093/europace/eux163 EHRA CONSENSUS DOCUMENT Device-detected subclinical atrial tachyarrhythmias: definition, implications and management an European Heart Rhythm Association
More informationSecondary Stroke Prevention: A Precautionary Tale
Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationHalf Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital
Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should
More informationAmbulatory Cardiac Monitors and Outpatient Telemetry Corporate Medical Policy
Ambulatory Cardiac Monitors and Outpatient Telemetry Corporate Medical Policy File Name: Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry File Code: UM.SPSVC.13 Origination: 10/2015 Last
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationATRIAL FIBRILLATION: IS IT REALLY TYPE 2 DIABETES MASQUERADING AS CARDIAC MISFORTUNE?
ATRIAL FIBRILLATION: IS IT REALLY TYPE 2 DIABETES MASQUERADING AS CARDIAC MISFORTUNE? ROBERT M PEPPER, DO, FAAFP ASSISTANT DEAN OF PRE DOCTORAL CLINICAL SCIENCES WEST VIRGINIA SCHOOL OF OSTEOPATHIC MEDICINE
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Clinical guideline for the management of atrial fibrillation
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Clinical guideline for the management of atrial fibrillation 1.1 Short title Atrial fibrillation 2 Background a) The National Institute
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationManagement of Atrial Fibrillation in the Hospitalized Patient
Management of Atrial Fibrillation in the Hospitalized Patient Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research:
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationAmbulatory Event Monitors and Mobile Cardiac Outpatient Telemetry
Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Policy Number: Original Effective Date: MM.02.021 02/01/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/28/2017
More informationAtrial Fibrillation. Why It s Important. Updated on 2007 / 11 / 23. Microlife Corp ww.microlife.com. Page 1
Atrial Fibrillation Why It s Important Microlife Corp ww.microlife.com Updated on 2007 / 11 / 23 Page 1 CONTENT ORIGINAL PRESENTATION P3 ~ P13 UPDATED ASH ABSTRACT SUBMISSION INFORMATION INTERESTING LINK
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationStuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med
Stuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med None There s no reason to panic. While it is true that one of the crew members is ill, slightly. Absence of discrete P waves Chaotic
More informationConsequences of stroke and AF
Consequences of stroke and AF Lorenzo G Mantovani Center of Pharmacoeconomics University of Naples Center for Public Health Research University of Milan Bicocca Questions Is stroke frequent? Is stroke
More informationAntony French Consultant Cardiologist & Electrophysiologist
Antony French Consultant Cardiologist & Electrophysiologist Palpitations Unpleasant awareness of rapid or forceful heart beat Not all tachycardias cause palpitations, and not all palpitations are due to
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationShould AF patients (after ablation) have anticoagulation forever? Can we ever stop it?
The 12 International Dead Sea Symposium - Jerusalem March 3-5 /2014 Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it? Antonio Raviele, MD, FESC, FHRS Past Director
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationUTILITY OF THE IMPLANTABLE LOOP RECORDER
UTILITY OF THE IMPLANTABLE LOOP RECORDER John Andriulli, DO Associate Professor of Medicine Director, Arrhythmia Device Program Cooper Medical School of Rowan University Contemporary Practices in Cardiology
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationFibrillazione atriale subclinica e rischio di ictus ischemico
Fibrillazione atriale subclinica e rischio di ictus ischemico Background 25% of all ischemic strokes are cryptogenic, and subclinical atrial fibrilla;on (AF) is suspected to be a possible cause in many
More informationRebuttal. Jerónimo Farré MD 2010
Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF
More informationDipen Shah Cardiology Service, University Hospitals, Geneva Switzerland
Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland Disclosures Research Grants: Biosense Webster, St. Jude, Bard, Endosense, Biotronik Speakers Honoraria: Biosense Webster, Endosense,
More information2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.
CRYPTOGENIC STROKE: 2017 Cardiovascular Symposium A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A. CRYPTOGENIC STROKE CRYPTOGENIC: OF OBSCURE OR UNKNOWN
More informationAblation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation
Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation 25 October 2008 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Assistant Professor
More informationProf. Fiorenzo Gaita
Adavances in Cardiac Arrhythmias and Great Innovations in Cardiology Turin 2014 Can rhythm control strategy reduce the risk of clinical and silent cerebral ischemia? Prof. Fiorenzo Gaita Director of the
More informationIS ATRIAL FIBRILLATION THE NEXT TYPE 2 DIABETES?
IS ATRIAL FIBRILLATION THE NEXT TYPE 2 DIABETES? ROBERT M PEPPER, DO, FAAFP ASSISTANT DEAN PREDOCTORAL CLINICAL EDUCATION WEST VIRGINIA SCHOOL OF OSTEOPATHIC MEDICINE IS ATRIAL FIBRILLATION THE NEXT TYPE
More informationTreatment strategy decision tree
strategy decision tree strategy decision tree Confirmed diagnosis of AF Further investigations and clinical assessment including risk stratification for stroke/thromboembolism Paroxysmal AF Persistent
More informationATRIAL FIBRILLATION AND LEFT ATRIUM: STRUCTURAL REMODELING AND EVOLUTION OF ARRHYTHMIA PATTERN
Atrial Fibrillation and Heart Failure: the ugly and the nasty 13 International Meeting February 14-15 th 2019, Bologna ATRIAL FIBRILLATION AND LEFT ATRIUM: STRUCTURAL REMODELING AND EVOLUTION OF ARRHYTHMIA
More informationFølgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved
. Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation
More informationΜηνύματα από τις σπουδαιότερες μελέτες στην ηλεκτροφυσιολογία το διάστημα
Μηνύματα από τις σπουδαιότερες μελέτες στην ηλεκτροφυσιολογία το διάστημα 2015-2016 Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou has received
More informationIctus criptogenetico: possiamo ridurre questa diagnosi?
FIBRILLAZIONE ATRIALE Ictus criptogenetico: possiamo ridurre questa diagnosi? Maurizio Landolina MD, FESC Direttore U.O.C. Cardiologia, Ospedale Maggiore di Crema Disclosures Speakers bureau appointment
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationPerformance of Atrial Fibrillation Detection in a New Single-Chamber ICD
DEVICES Performance of Atrial Fibrillation Detection in a New Single-Chamber ICD ABHISHEK DESHMUKH, M.D.,* MARK L. BROWN, PH.D., ELISE HIGGINS, B.S., BRIAN SCHOUSEK, B.S., ATHULA ABEYRATNE, PH.D., GIOVANNI
More informationManagement and Investigation of Ischemic Stroke By Etiology
Management and Investigation of Ischemic Stroke By Etiology Andrew M. Demchuk MD FRCPC Director, Calgary Stroke Program Deputy Dept Head, Clinical Neurosciences Heart and Stroke Foundation Chair in Stroke
More informationAtrial fibrillation: current approaches to management
DRUG REVIEW n Atrial fibrillation: current approaches to management Upasana Tayal MA, MRCP and Robert Greenbaum BSc, MD, FRCP, FESC, FACC Atrial fibrillation is the commonest arrhythmia and GPs have an
More informationDysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics
Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise
More informationMANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017
MANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017 1 Faculty Disclosure Faculty: Peter Leong-Sit MSc, MD, FRCPC, FHRS Associate Professor, Western University Cardiologist, London Heart
More informationCryptogenic Strokes: Evaluation and Management
Cryptogenic Strokes: Evaluation and Management 77 yo man with hypertension and hyperlipidemia developed onset of left hemiparesis and right gaze preference, last seen normal at 10:00 AM Brought to ZSFG
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ambulatory Event Monitors and Mobile
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationAF burden is important fact or fiction?
REVIEW ARTICLE AF burden is important fact or fiction? G. Boriani, I. Diemberger, M. Ziacchi, C. Valzania, B. Gardini, P. Cimaglia, C. Martignani, M. Biffi Linked Comment: Lip. Int J Clin Pract 2014; 68:
More information